Improving Outcomes with Clinical Practice Guidelines for Myeloproliferative Neoplasms

Share this content:
New NCCN guidelines should serve to standardize care for myelofibrosis, ET, and PV.
New NCCN guidelines should serve to standardize care for myelofibrosis, ET, and PV.

New guidelines from the National Comprehensive Cancer Network (NCCN) for myeloproliferative neoplasms (MPN) were developed to standardize care and improve outcomes in for patients with myelofibrosis, essential thrombocythemia (ET), or polycythemia vera (PV).  The new guidelines fill a significant void in the treatment of MPN.

NCCN published the guidelines for MPN to specifically outline diagnosis, treatment, and supportive care strategies for myelofibrosis. The current guidelines document evidence-based consensus-driven management. 

They are designed to ensure that all patients receive preventive, diagnostic, treatment, and supportive care services that are most likely to lead to optimal outcomes. The guidelines authors contend that the management of MPNs has been variable in the past, due in part to clinicians largely having to rely on review articles and individual opinions for guidance. The authors hope this tool will help clinicians with making treatment decisions.

With the publication of the NCCN Guidelines for MPN, the library of NCCN Guidelines now includes more than 60 clinical guidelines detailing sequential management decisions and interventions that currently apply to 97% of cancers affecting people in the United States.


1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myeloproliferative Neoplasms. Version 2.2017. Accessed May 9, 2017.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs